Seaport Therapeutics is a clinical-stage therapeutics company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary GlyphTM technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit www.seaporttx.com.

The Role

Seaport Therapeutics is hiring an Associate Director, Program Management to lead integrated planning and execution for a clinical-stage program. Reporting to the Director of Program Management, this role partners with the Program Leader and the cross-functional program team — Clinical Development, Clinical Operations, Regulatory, Technical Operations (CMC), and Nonclinical Development — to deliver program milestones on time in a high-functioning program team environment.

In the near term, the role will focus on establishing integrated development plans, timelines, and risk management for the program and on running an effective program team operating rhythm. This role will also continue to build Seaport's program management capability, standardizing the tools, templates, and processes used across the portfolio and contributing to company-wide resource and investment planning.

The ideal candidate will embrace a collaborative, innovative culture that embodies our values of service to patients impacted by mental health conditions, with a "we own it" mentality, demonstrating entrepreneurial spirit and technical excellence while fostering teamwork and continuous improvement. This position is based in Boston's Seaport area, with a strong preference for being onsite 4 days per week.

Key Responsibilities

Develop and maintain integrated development plans, timelines, milestones, risks, and scenarios in partnership with the Program Leader, functional leaders, and program team members across Clinical Development, Clinical Operations, Regulatory, Technical Operations (CMC), and Nonclinical Development.
Own the program’s core planning documents, including the integrated timeline, risk plan, dashboards, and status updates.
Serve as the central point of contact for the program team on issue identification, resolution, and escalation, and partner with the Program Leader to keep the team operating effectively.
Facilitate program team and subteam meetings, including agendas, prereads, minutes, and action item follow-through; stand up and manage ad hoc workstreams as needed.
Support the Program Leader in delivering clear, timely updates on program progress, risks, and decisions to the Executive Leadership Team.
Support cross-functional resource, budget, and capacity planning for assigned program(s), and contribute to annual budget and long-range planning.
Build and maintain the program’s document-sharing environment to support team communication and institutional knowledge capture.
Champion program management best practices, including contemporary templates, tools, and processes that improve efficiency, decision-making, and communication.

Qualifications

8+ years of pharmaceutical or biotech industry experience, including 3+ years in program, portfolio, or alliance management.
BA/BS in a scientific, engineering, business, or related discipline; an advanced degree (PhD, MS, MBA) is preferred.
Direct experience working with Clinical Development, Clinical Operations, Regulatory, Technical Operations (CMC), and Nonclinical Development.
Working knowledge of the drug discovery, development, and commercialization process, with depth in mid- and late-stage clinical execution.
Track record of guiding cross-functional teams through complex scientific, regulatory, and development challenges, and of influencing without direct authority.
Strong analytical and problem-solving skills, with the ability to hold both detail and strategic context.
Excellent written and verbal communication, including executive-level presentation and meeting facilitation skills.
Ability to manage multiple priorities across programs and functions in a fast-paced, high-visibility environment.
Neuroscience or neuropsychiatric development experience is a plus; passion for Seaport’s patient-centric mission is essential.
Core Technical Competencies in project and portfolio management platforms; proficiency in Smartsheet is required; experience with enterprise PPM tools (e.g., Microsoft Project, Planisware, Planview), Microsoft Office suite, and AI LLM tools are preferred.

At Seaport, we believe transparency and fairness are key to building a culture of trust, respect, and collaboration. We care deeply about the happiness of our team and strive to ensure our total rewards (monetary and non-monetary) program reflects the value each person brings. The expected salary range for this role is $180,000–$205,000, with the final offer based on level, experience, market data, and internal equity. We encourage open conversations with our talent acquisition team about compensation early in the process to ensure alignment from the start.

About the company

Seaport Therapeutics develops new antidepressants and anxiolytics for neuropsychiatric disorders. Its products are designed to be orally bioavailable and to avoid first-pass metabolism while minimizing hepatotoxicity and other side effects. The company advances drug candidates through clinical trials and regulatory approval with the aim of commercialization, either directly or via partnerships and licensing with larger pharmaceutical companies. The team combines biotech industry experience to support development and execution. Unlike some peers, Seaport focuses on PK properties that improve oral bioavailability and safety, aiming for drugs that patients can take easily and with fewer liver-related risks. The overarching goal is to bring safe, effective neuropsychiatric medications to patients by progressing through development to market, leveraging partnerships to scale.

Company Size

51-200

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

2024

Get referred to Seaport Therapeutics

See people who can refer or advise you

Simplify's Take

What believers are saying

September 9, 2026 driving data showed GlyphAllo preserved next-morning driving performance.
August 3, 2026 cash of $427.3 million funds operations into 2029.
March 3, 2026 ARPA-H awarded Seaport and Monash up to $15 million for GlyphCele.

What critics are saying

BUOY-1 topline in 1H 2027 is binary; failure kills GlyphAllo valuation.
Seaport still has no revenue; every program depends on future financings and approvals.
Competitive pressure from CAPLYTA and other antidepressants will blunt launch pricing in 2027.

What makes Seaport Therapeutics unique

Seaport's Glyph platform turns validated CNS drugs oral by bypassing first-pass metabolism.
Daphne Zohar and Steven Paul bring Karuna-style neuropsychiatric execution credibility.
GlyphAllo targets allopregnanolone, a clinically validated mechanism with differentiated oral delivery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

6 month growth

1 year growth

2 year growth

19%

Biotech Today

Oct 11th, 2026

Seaport adds GlyphAgo drug-exposure data at ECNP Congress.

Seaport adds GlyphAgo drug-exposure data at ECNP Congress. Seaport's additional GlyphAgo pharmacokinetic data address drug exposure in early development, but do not by themselves establish clinical benefit. Key facts. * Developer: Seaport Therapeutics, a PureTech-founded entity * Candidate: GlyphAgo * Clinical update: Additional pharmacokinetic data from a Phase 1 trial * Presentation venue: 39th European College of Neuropsychopharmacology Congress Seaport Therapeutics, a PureTech-founded entity, presented additional pharmacokinetic data from a Phase 1 clinical trial of GlyphAgo at the 39th European College of Neuropsychopharmacology Congress. Seaport Therapeutics, a PureTech-founded entity, presented additional pharmacokinetic data from its Phase 1 clinical trial of GlyphAgo at the 39th European College of Neuropsychopharmacology (ECNP) Congress. The update concerns an early question in drug development: how a compound moves through the body after it is administered. That question matters before a developer can confidently select a dosing approach for subsequent studies. Pharmacokinetics describes how the body absorbs, distributes, metabolizes and eliminates a drug. It is distinct from evidence that a treatment improves symptoms or produces a meaningful clinical benefit. The presentation was reported by Business Wire. The verified information establishes the study stage, the type of data and the presentation venue, but supplies no numerical findings from which to judge GlyphAgo's exposure profile. Drug exposure helps shape the dosing decision. Pharmacokinetic measurements can help researchers understand how quickly a drug reaches the bloodstream, how high its concentration rises and how long exposure persists. Those features can inform the amount administered and the interval between doses. They can also reveal whether apparently similar doses produce substantially different exposure among participants. For GlyphAgo, the key analytical distinction is between the existence of additional data and what those data demonstrate. A presentation adds information to the development record. It does not, without the underlying findings, establish that absorption is improved, exposure is predictable or a particular dosing schedule is suitable. Several kinds of measurements would help make that assessment. Peak concentration describes the highest measured level in the bloodstream. Total exposure summarizes drug concentration over time. Half-life describes how long it takes for the measured concentration to fall by half under the relevant conditions. These are general pharmacokinetic concepts, not reported GlyphAgo results. The relationship between dose and exposure is also important. If increasing a dose produces a broadly proportional increase in exposure, study planning may be more straightforward. If that relationship is uneven, researchers may need to examine the reasons and adjust their approach. No such relationship can be assigned to GlyphAgo from the confirmed presentation facts alone. Phase 1 evidence is not an efficacy verdict. Phase 1 trials generally focus on early human evaluation, including safety, tolerability and drug exposure. Their design can vary, and some may explore other outcomes. The phase designation by itself does not establish who participated, what doses were used or whether the trial was designed to test a treatment effect. That limitation is central to interpreting Seaport's announcement. Additional pharmacokinetic findings may help a development team decide how to study a candidate further. They should not be read as proof that the candidate treats a disease, outperforms another therapy or is ready for regulatory approval. Exposure and clinical response are connected questions, but they are not interchangeable. A drug can reach measurable concentrations without producing the intended effect. Conversely, understanding exposure can help explain why a response differs across participants. Establishing those connections requires appropriate clinical measurements and a study capable of supporting the conclusion. Exposure and clinical response are connected questions, but they are not interchangeable. Safety must remain part of the same assessment. A higher concentration is not automatically a better outcome, because useful exposure has to be considered alongside adverse effects and tolerability. The supplied facts do not establish a favorable or unfavorable safety profile for GlyphAgo, so neither conclusion is warranted. The details that would make the update actionable. For researchers and investors, the next useful step is to examine the actual exposure findings and the conditions under which they were collected. Participant characteristics, dosing conditions, sampling methods and variability all affect how readily results can inform another study. A headline about additional data cannot substitute for those details. Consistency across participants would be particularly relevant to dose selection. An average exposure result can conceal a wide spread of individual responses. Understanding that spread helps researchers assess whether a proposed regimen is likely to produce reasonably consistent exposure or requires further investigation. Repeat administration can raise different questions from an initial dose. Depending on a drug's properties, concentrations may accumulate or change over time. Whether the GlyphAgo presentation addresses repeat dosing is not established by the available facts. It is therefore a question to examine, not a feature to assume. Another distinction is between measuring a drug in blood and demonstrating its action at the intended biological site. Blood concentrations can be informative, but they do not automatically establish activity in a particular tissue or engagement with a biological target. Any claim along those lines would require its own supporting evidence. Seaport's development progress remains the focus. Seaport's connection to PureTech identifies the company's founding relationship. It does not, on the supplied information, establish ownership economics, funding commitments or the financial value of GlyphAgo. The confirmed event is a scientific presentation, not a financing, licensing transaction or commercial launch. For investors following the program, the practical issue is whether the additional data reduce uncertainty about how GlyphAgo can be studied. Evidence that helps select a dose or refine a protocol can be useful even before efficacy is demonstrated. Its value depends on the findings and their relevance to subsequent development decisions. The ECNP presentation provides a setting for scientific scrutiny, but attendance at a congress is not regulatory clearance or independent confirmation of therapeutic benefit. The appropriate test remains the substance of the evidence: what was measured, how reliably it was measured and what conclusions the trial design supports. Seaport has added pharmacokinetic information to GlyphAgo's Phase 1 development record. Whether that information supports a clear dosing strategy or a broader development advance cannot be determined from the confirmed facts alone. The next meaningful assessment rests on the exposure results and any supported decisions about further clinical testing. Frequently asked questions. What did Seaport Therapeutics present about GlyphAgo? Seaport Therapeutics presented additional pharmacokinetic data from a Phase 1 clinical trial of GlyphAgo at the 39th European College of Neuropsychopharmacology Congress. The confirmed information identifies the candidate, study stage and type of findings, but does not supply numerical results that would establish how favorable its drug-exposure profile is. What does pharmacokinetic data measure? Pharmacokinetic data describe how the body absorbs, distributes, metabolizes and eliminates a drug. Measurements can address peak concentration, exposure over time and how quickly concentrations decline. Researchers use this information to help evaluate dosing approaches, but drug exposure alone does not establish that a treatment produces clinical benefit. Does the GlyphAgo presentation prove the drug works? The confirmed presentation facts do not establish that GlyphAgo works as a treatment. Pharmacokinetic findings concern drug exposure, which is different from evidence of improvement in symptoms or other clinical outcomes. Assessing efficacy requires relevant outcome measurements and a trial design capable of supporting a conclusion about treatment benefit. Why can Phase 1 exposure findings matter for later trials? Early exposure findings can help researchers choose doses, consider dosing intervals and understand differences among participants. They may also help interpret safety observations. For GlyphAgo, those potential uses should be distinguished from demonstrated conclusions: the supplied facts do not identify the exposure results or confirm a subsequent clinical testing plan. What is Seaport Therapeutics' relationship to PureTech? Seaport Therapeutics is identified as a PureTech-founded entity. That establishes a founding relationship, but the supplied information does not specify current ownership, financial obligations or the economic value of GlyphAgo to PureTech. The announced event concerns clinical pharmacokinetic data rather than a funding transaction or a commercial agreement. What should readers examine next in GlyphAgo's development? Readers should examine the underlying exposure results, variability among participants, dosing conditions and accompanying safety evidence. Any supported decision about further testing would also matter. A congress presentation is a scientific communication event, not regulatory approval, and its significance depends on the findings and the conclusions the study design can support.

Seaport Therapeutics

Sep 12th, 2026

Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

Financing led by General Atlantic with participation from T. Rowe Price Associates, Foresite Capital, Invus, Goldman Sachs Alternatives, Canada Pension Plan Investment Board (CPP Investments) as well as other new investors

London South East

Sep 9th, 2026

EARNINGS AND TRADING: Pebble Beach revenue grows as forecast.

EARNINGS AND TRADING: Pebble Beach revenue grows as forecast. Wed, 09th Sep 2026 19:21 (Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Pebble Beach Systems Group PLC - Surrey, England-based software company - Reports results for the first half of 2026. Revenue increases 10% to GBP6.5 million from GBP5.9 million, in line with company guidance. Recurring revenue increases 6% to GBP3.4 million from GBP3.3 million. Adjusted earnings before interest, tax, depreciation and amortisation rise 25% to GBP2.5 million from GBP2.0 million. Pretax profit more than triples to GBP1.8 million from GBP465,000. Adjusted pretax profit climbs 73% to GBP1.9 million from GBP1.1 million. Looking ahead, Pebble Beach says it "is very well-positioned with a strong order book, increased recurring revenue, very healthy cash flows and an encouraging pipeline of new opportunities," and "is confident of continuing progress in the current financial year and beyond." Carclo PLC - London-based provider of precision components - Closes down 5.9% in London after releasing a trading update. Says trading in its current financial year to date, starting April 1, has shown a strong margin performance with underlying operating profit and return on sales both in line with internal expectations. However, year-to-date revenue is "slightly behind the same period in the prior year," which Carclo says reflects the phasing of Design & Engineering tooling programmes and a slow first quarter for Manufacturing Solutions volumes, although volumes are recovering going into the second quarter. Says Aerospace demand is still high and parts of Life Science "continue to perform well, while demand from certain diagnostics customers remains softer." Says net debt as of July 31 was higher than at the end of its latest financial year, "due to both the extension of leases to existing US properties and the timing of working capital flows." Expects the outflow to reverse by the end of the second quarter, with net debt excluding leases at the end of the first half back in line with the year-end total. "Order activity and new programme launches support positive organic revenue growth for the full year," Carclo says. "The board's expectations for the full year remain unchanged, and in line with the previously communicated targets under the Precision 2030 growth plan." Made Tech Group PLC - London-based provider of digital, data and technology services to the UK public sector - Closes up 6.3% after announcing its selection as a supplier to three lots under the Met Office's new Delivery Partnerships Framework 2, "a four-year framework intended to support the development and delivery of future technology solutions across the full lifecycle of Met Office products & services." Made Tech says it was successful in all three lots for which it tendered, providing "potential future contract wins as contracts are awarded over the four year term". Notes however that it has won no contracts at this stage, and will announce any awarded as appropriate. "As is customary with public sector frameworks of this nature, there is no guaranteed level of expenditure or revenue attributable to Made Tech," it adds. Believes its selection for Lot 3 is "of particular strategic importance," as it "covers work requiring higher levels of security clearance," thereby leaving an opening "to compete for a broader range of higher-security government work". This "represents important progress in the group's strategy to build its presence in the Defence sector, leveraging the capabilities and experience it has developed across Public Safety and Central Government." PureTech Health PLC - Boston, Massachusetts-based biotech and pharmaceutical company - Founded entity Seaport Therapeutics reports positive topline results from the phase 1 Driving Simulation Trial of GlyphAllo, also known as SPT-300 or Glyph Allopregnanolone, in healthy participants. Says the trial met its primary endpoint, demonstrating that evening dosing of GlyphAllo at 375 milligrams did not impair next-morning driving performance, compared to a placebo, on day 5. Says Seaport plans to submit the results to the US Food & Drug Administration as part of the ongoing development program for GlyphAllo. GlyphAllo is in development as a potential treatment of major depressive disorder. PureTech adds that Seaport is enrolling patients in the BUOY-1 phase 2b trial to investigate the safety and efficacy of GlyphAllo in patients with MDD, with or without anxious distress. Expects topline results in the first half of 2027. Fusion Antibodies PLC - Belfast-based contract researcher providing discovery, design and optimisation services for therapeutic antibodies - Canadian Intellectual Property Office grants its CA 3115150 patent application, entitled 'Antibody Library and Method'. It covers two families of antibodies, and the method for the design of such antibody libraries. Fusion expects the patent to complement its offering to provide 'Opti' designed antibody libraries for various applications, including antibody discovery, affinity maturation, and sequence optimisation. Says it continues to progress additional patent applications regarding the OptiMAL Library in several other regions, including Europe and China. By Emma Curzon, Alliance News reporter Shares in this article. Pebble Beach 26.00 0.00% 35.00 -5.91% 48.50 5.43% 120.80 -0.49% Fusion Antibodies 11.25 -2.17%

Financial Times

Aug 31st, 2026

Seaport Therapeutics to present at Citi's 2026 Biopharma Back to School Conference and participate in 21st Annual Wells Fargo Healthcare Conference.

Seaport Therapeutics to present at Citi's 2026 Biopharma Back to School Conference and participate in 21st Annual Wells Fargo Healthcare Conference. Aug 31 2026 12:00 BST BOSTON-(BUSINESS WIRE)-Aug. 31, 2026- Seaport Therapeutics, Inc. (Nasdaq: SPTX) ("Seaport" or the "Company"), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in the following upcoming investor conferences: * 21st Annual Wells Fargo Healthcare Conference * September 8-10, 2026 * Seaport will participate in one-on-one investor meetings * Citi's 2026 Biopharma Back to School Conference * September 9-10, 2026 * Fireside chat: September 9, 2026 at 1:00 p.m. ET * Seaport will participate in one-on-one investor meetings A live webcast of the Citi fireside chat will be available on the Investors section of the Company's website at. An archived replay will be available following the presentation.

BioSpace

Aug 5th, 2026

5 NextGen winners who went public this year (and which ones are hiring).

5 NextGen winners who went public this year (and which ones are hiring). August 5, 2026 | BioSpace NextGen honorees made up one-third of the U.S. biotechs that have publicly debuted in 2026. Most are looking for biopharma professionals to join their teams. Of the 14 U.S. biotechs that went public this year, five once landed on the BioSpace NextGen list of the most promising up-and-coming life sciences companies. Together, their initial public offerings raised about $1.5 billion, including exercises of underwriters' options to purchase additional shares of stock. Biopharma professionals looking for their next opportunities may want to check out these biotechs, especially given that four are hiring now. Below are snapshots of each business. Kardigan. Launched in January, Kardigan is developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. The NextGen Class of 2026 winner raised $460 million with its initial public offering, including the full exercise of the underwriters' option to purchase additional shares of stock. Kardigan is based in South San Francisco, California, and Princeton, New Jersey. The company's pipeline consists of three late-stage clinical programs, of which danicamtiv is the furthest along. Kardigan's direct myosin activator is being studied in a Phase 2b/3 clinical trial for the treatment of genetic dilated cardiomyopathy. The disease affects the heart's lower and upper chambers, making it difficult for the muscle to pump blood. Three former leaders of MyoKardia, a cardiology-based biotech Bristol Myers Squibb bought in 2020 for $13.1 billion, co-founded Kardigan. Tassos Gianakakos is now Kardigan's CEO and chair, Jay Edelberg is its chief medical officer and Bob McDowell is its scientific adviser. While at MyoKardia, a NextGen Class of 2015 winner, the three led the development of mavacamten, the first FDA-approved cardiac myosin inhibitor that targets the source of obstructive hypertrophic cardiomyopathy. Kardigan has over 30 roles open, including associate director, insights and analytics; clinical trial manager; and associate director, regulatory strategy. Seaport Therapeutics. Based in Boston, Seaport Therapeutics is developing medicines for the treatment of depression, anxiety and other neuropsychiatric disorders. The NextGen Class of 2025 winner uses a proprietary platform to advance drugs previously limited by high first-pass metabolism, low bioavailability and side effects. Seaport raised $260 million with its upsized initial public offering. Launched in 2024, the company has a pipeline of three programs, including lead asset GlyphAllo (SPT-300) for the treatment of major depressive disorder (MDD). The oral prodrug of allopregnanolone, a naturally occurring neurosteroid, is being studied in a Phase 2b trial in patients with MDD and a Phase 1 driving simulation trial in healthy volunteers. Topline data is expected in the second half of this year for the Phase 1 study and the first half of 2027 for Phase 2b. Two former Karuna Therapeutics leaders founded Seaport. Daphne Zohar is now Seaport's CEO and a board member, while Steven Paul is its board chair. Bristol Myers Squibb acquired Karuna in 2023 for $14 billion. Seaport has several roles open, including clinical trial manager; senior scientist, bioanalytical science; and director, clinical quality assurance. Odyssey Therapeutics. Launched in 2021, Odyssey Therapeutics is developing medicines for the treatment of autoimmune and inflammatory diseases. The NextGen Class of 2023 winner's therapies target initial immune responses with the goal of preventing pathologic inflammation from starting. Boston-based Odyssey raised about $315 million with its initial public offering, including the partial exercise of the underwriters' option to purchase additional shares of stock. The biotech's pipeline of small molecule and protein therapeutics consists of six programs, which includes RIPK2 (OD-001). The RIPK2 scaffolding inhibitor was designed for the treatment of ulcerative colitis and Crohn's disease, both inflammatory bowel diseases. Odyssey plans to start a Phase 2b monotherapy trial as well as a Phase 2a combination trial with vedolizumab, a humanized monoclonal antibody developed by Takeda and marketed as Entyvio, in the second half of this year. The biotech expects results from both studies in H2 2027. Odyssey's leadership team includes serial biotech entrepreneur Gary Glick, the company's founder, president and CEO. Glick also founded IFM Therapeutics, Scorpion Therapeutics (a NextGen Class of 2022 winner) and First Wave BioPharma. Odyssey has several roles open, including clinical trial manager II, computational biologist and senior clinical data manager. Eikon Therapeutics. Based in Millbrae, California, Eikon Therapeutics develops medicines for the treatment of serious illnesses, with a goal to introduce therapies that improve and extend life. A NextGen Class of 2022 winner, Eikon launched in 2021 and raised $381 million this year with its upsized initial public offering. The company's pipeline consists of five oncology programs at various stages of development as well as discovery work in oncology and neurologic diseases. Programs include EIK1001, a dual agonist of toll-like receptors 7 and 8 being developed for the treatment of melanoma and non-small cell lung cancer (NSCLC). Eikon recently dosed its first patient in a Phase 2/3 registrational study evaluating EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy as a first-line therapy for patients with stage 4 NSCLC. Pembrolizumab is a humanized monoclonal antibody developed by Merck and marketed as Keytruda. Eikon's leadership team includes CEO Roger Perlmutter, previously the president of Merck Leadership Laboratories. While at Merck, he supervised the discovery and development of medicines including Keytruda. Eikon has around a dozen roles open, including principal scientist, computational chemistry; director, regulatory affairs; and director, clinical quality assurance (GCP). Scribe Therapeutics. Scribe Therapeutics, which emerged from stealth mode in 2020, engineers CRISPR-based technologies into in vivo genetic medicines for the treatment of highly prevalent diseases. The NextGen Class of 2021 winner's initial programs focus on addressing key drivers of atherosclerotic cardiovascular disease (ASCVD). Based in Alameda, California, Scribe raised about $155 million with its initial public offering, including the full exercise of the underwriters' option to purchase additional shares of stock. The company's pipeline includes three programs with identified targets and one with an undisclosed cardiometabolic target. Scribe's lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene and reduce LDL-C levels without causing permanent DNA changes. The company recently received approval from the Australian Therapeutic Goods Administration to begin human testing of STX-1150 for the treatment of hypercholesterolemia, a major driver of ASCVC. Scribe was co-founded by Jennifer Doudna, who co-discovered CRISPR-Cas9 genetic engineering technology with French scientist Emmanuelle Charpentier. In 2020, the pair received a Nobel Prize in Chemistry for developing the genome editing method. Job market trends, layoffs and career advice to manage your life sciences career Angela Gabriel is content manager, life sciences careers, at BioSpace. She covers the biopharma job market, job trends and career advice, and produces client content. You can reach her at [email protected] and follow her on LinkedIn.